Also known as: Byetta, Bydureon, exendin-4, AC2993
Type 2 diabetes glycemic control
Amount
5-10 mcg BID (Byetta) or 2 mg weekly (Bydureon BCise)
Frequency
Twice daily (Byetta) or once weekly (Bydureon BCise)
Duration
Ongoing (chronic therapy)
Step-wise Titration (4 weeks)
Route
SCSchedule
Twice daily (Byetta) or once weekly (Bydureon BCise)
Timing
Byetta: within 60 minutes before meals; Bydureon BCise: any time, any day
✓ Rotate injection sites
Duration
Ongoing (chronic therapy)
Repeatable
Yes
✓ Ready-to-use — no reconstitution required
Storage: Byetta: refrigerate or room temp up to 30 days after first use. Bydureon BCise: refrigerate or room temp up to 4 weeks.
HbA1c and fasting glucose
When: Baseline
Why: Baseline glycemic control
Lipid panel
When: Baseline
Why: Baseline cardiovascular markers
CMP with renal function
When: Baseline
Why: Kidney function (renal elimination)
Thyroid panel (TSH, free T4)
When: Baseline
Why: Rule out thyroid disorders (black box MTC warning)
Amylase and lipase
When: Baseline
Why: Baseline pancreatic function
HbA1c
When: 12 weeks
Why: Monitor glycemic improvement
Get weekly peptide research summaries, new study alerts, and protocol updates — free.
150+ peptide profiles · 30+ comparisons · 18 research tools
Exenatide is a 39-amino-acid peptide that is the synthetic form of exendin-4, a naturally occurring peptide discovered in 1990 by Dr. John Eng in the saliva of the Gila monster lizard (Heloderma suspectum). Exendin-4 shares approximately 53% amino acid sequence homology with human glucagon-like peptide-1 (GLP-1) and functions as a potent GLP-1 receptor agonist.
Exenatide holds watershed significance in pharmacology as the first GLP-1 receptor agonist approved by the FDA, launching the entire incretin mimetic drug class that now includes semaglutide, liraglutide, tirzepatide, and many others. It is marketed under two brand names:
The discovery of exenatide illustrates how basic research in unexpected places can yield transformative medicines. Dr. John Eng, an endocrinologist at the VA Medical Center in the Bronx, New York, investigated Gila monster venom after learning that the lizard can survive long periods without eating while maintaining stable blood glucose. He isolated exendin-4 from the venom and demonstrated that it stimulated insulin secretion from pancreatic beta-cells in a glucose-dependent manner.
Amylin Pharmaceuticals subsequently developed synthetic exendin-4 (designated AC2993, later named exenatide) through clinical trials, partnering with Eli Lilly for commercialization. In 2012, Dr. Eng was co-awarded the Golden Goose Award by the U.S. Congress, recognizing seemingly unconventional research that led to major public benefit.
Exenatide activates the GLP-1 receptor, mimicking and extending the effects of the endogenous incretin hormone GLP-1. Despite only 53% sequence homology with human GLP-1, exenatide binds to and activates the GLP-1 receptor with comparable potency.
Unlike liraglutide and semaglutide, which are modified versions of the human GLP-1(7-37) peptide, exenatide is an entirely different peptide sequence derived from a reptilian source. The key advantage of this natural exendin-4 sequence is inherent resistance to DPP-4 enzymatic degradation (the enzyme that rapidly inactivates native GLP-1), without needing the artificial modifications (e.g., Aib substitutions) used in human GLP-1 analogs.
Exenatide's evidence base spans the AMIGO phase 3 trials (twice-daily), DURATION trials (once-weekly), and the large EXSCEL cardiovascular outcomes trial (14,752 patients). While superseded by newer GLP-1 agonists for glycemic efficacy, exenatide maintains unique research interest for potential neuroprotective applications in Parkinson's disease.
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL), published in New England Journal of Medicine (Holman RR et al., 2017; PMID: 28910237):
We summarize new studies, safety updates, and dosing insights — delivered biweekly.
See real-world usage patterns alongside the clinical evidence above. Community-sourced, not clinically verified.
Based on 30+ community reports
View community protocolsYes. Exenatide is a synthetic version of exendin-4, a peptide discovered in 1990 by Dr. John Eng in the saliva of the Gila monster lizard (Heloderma suspectum). Exendin-4 shares 53% amino acid homology with human GLP-1 but is naturally resistant to DPP-4 degradation, giving it a much longer half-life than native GLP-1.
Both contain exenatide but in different formulations. Byetta is an immediate-release injection given twice daily (5-10 mcg) within 60 minutes before meals. Bydureon BCise is an extended-release microsphere formulation given once weekly (2 mg) without regard to meals.
Semaglutide is a newer, more potent GLP-1 agonist with substantially greater efficacy for both HbA1c reduction and weight loss. Semaglutide achieves 14.9% weight loss versus 2-3% with exenatide. However, exenatide has the longest safety track record of any GLP-1 RA (since 2005) and unique research in Parkinson's disease neuroprotection.
Early clinical evidence is promising. A 2017 randomized trial (Athauda et al., Lancet) showed exenatide significantly reduced deterioration in motor symptoms in Parkinson's disease patients. A larger phase 3 trial has been completed. GLP-1 receptor activation may have neuroprotective effects through anti-inflammatory and neurotrophic mechanisms.
Semaglutide: FDA-approved GLP-1 agonist for weight loss and diabetes. Covers STEP/SUSTAIN trials, Ozempic vs Wegovy dosing, and cardiovascular benefits.
Liraglutide: FDA-approved GLP-1 receptor agonist for type 2 diabetes and weight management. Covers LEADER cardiovascular trial, SCALE weight loss data, and Victoza/Saxenda dosing.
Tirzepatide: FDA-approved dual GIP/GLP-1 agonist with up to 22.5% weight loss. Covers SURPASS/SURMOUNT trials, dosing, and semaglutide comparison.
GLP-1: Incretin hormone powering modern weight loss drugs. Covers insulin secretion, satiety signaling, semaglutide and liraglutide data, and safety.
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.
Liraglutide is superior to exenatide across all major clinical dimensions. The LEAD-6 head-to-head trial demonstrated greater HbA1c reduction (1.12% vs 0.79%), fewer hypoglycemia events, and better tolerability. Liraglutide also has an FDA-approved obesity indication (Saxenda, 8.0% weight loss in SCALE), proven cardiovascular benefit (LEADER, 13% MACE reduction), and once-daily dosing without microsphere-related injection site reactions. Exenatide retains historical significance as the first GLP-1 agonist and may serve as a lower-cost option in resource-limited settings, but liraglutide is the preferred agent for new prescriptions among these two options.
Semaglutide is substantially superior to exenatide in weight loss efficacy (14.9% vs 2-4%), glycemic control (SUSTAIN 3 head-to-head), cardiovascular outcomes (proven superiority vs non-inferiority only), and dosing convenience (pre-filled weekly pen vs reconstitution). Exenatide holds historical significance as the first GLP-1 agonist (FDA 2005) and may still serve as a lower-cost alternative in markets where newer agents are unavailable. However, for most clinical applications, semaglutide has effectively superseded exenatide.
A mid-2026 review of liraglutide (Saxenda, Victoza) side effects covering GI tolerability, cardiovascular safety from LEADER, long-term post-marketing signals, and how the profile compares to semaglutide, tirzepatide, and retatrutide.
History of peptide research from insulin's 1921 discovery to modern GLP-1 agonists. Key milestones in synthesis and therapeutics.
Calculate human equivalent doses from animal studies using FDA body surface area scaling. Covers the HED formula and common mistakes.
A research review tracing the evolution of GLP-1 receptor agonists from semaglutide through tirzepatide, retatrutide, and survodutide, examining how multi-receptor approaches have progressively expanded efficacy in obesity and metabolic disease.
Related content you may find interesting